Anavex Life Sciences has reported ongoing long-term benefits from its investigational drug blarcamesine in patients with Alzheimer’s disease, based on results from an open-label extension study. According to the company, participants receiving oral blarcamesine showed continued cognitive and functional stability over several years compared to a decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) control group.
The company said that the findings reinforce blarcamesine’s potential to modify disease progression, suggesting that treatment may preserve cognitive performance and daily living abilities over time. The long-term data were derived from clinical trial participants who completed previous double-blind studies and continued in open-label treatment, allowing for the observation of sustained outcomes across multiple measures of cognitive health.
Anavex stated that the analysis compared patient outcomes to those from the ADNI dataset, a major observational study tracking the natural course of Alzheimer’s disease in untreated individuals. The company claims that the results demonstrate a significant divergence in disease trajectory between treated and control groups, with blarcamesine showing a favorable safety profile throughout the study period.
According to the company, these findings support further clinical development of blarcamesine as a potential therapy targeting underlying mechanisms of neurodegeneration. Anavex added that additional analyses are ongoing to assess broader implications of the drug’s impact across neurodegenerative disorders, including Parkinson’s disease and Rett syndrome.
The post Anavex Life Sciences reports sustained benefits from oral blarcamesine appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
